Loading...

We've got a brand new version of Simply Wall St! Try it out

Cellmid

ASX:CDY
Snowflake Description

Mediocre balance sheet with weak fundamentals.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
CDY
ASX
A$21M
Market Cap
  1. Home
  2. AU
  3. Pharmaceuticals & Biotech
Company description

Cellmid Limited, a life sciences company, develops and commercializes diagnostic and therapeutic products for cancer and various chronic inflammatory conditions in Australia, the United States, and Japan. The last earnings update was 82 days ago. More info.


Add to Portfolio Compare Print
CDY Share Price and Events
7 Day Returns
9.5%
ASX:CDY
4.7%
AU Biotechs
0.9%
AU Market
1 Year Returns
-30.3%
ASX:CDY
50.9%
AU Biotechs
16.3%
AU Market
CDY Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Cellmid (CDY) 9.5% 17.9% 7% -30.3% -60.3% -61.7%
AU Biotechs 4.7% 8.7% 20% 50.9% 168.8% 226.4%
AU Market 0.9% 1.9% 5.1% 16.3% 22.3% 22.5%
1 Year Return vs Industry and Market
  • CDY underperformed the Biotechs industry which returned 50.9% over the past year.
  • CDY underperformed the Market in Australia which returned 16.3% over the past year.
Price Volatility
CDY
Industry
5yr Volatility vs Market

Value

 Is Cellmid undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Cellmid. This is due to cash flow or dividend data being unavailable. The share price is A$0.23.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Cellmid's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Cellmid's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
ASX:CDY PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-06-30) in AUD A$-0.08
ASX:CDY Share Price ** ASX (2019-11-17) in AUD A$0.23
Global Biotechs Industry PE Ratio Median Figure of 145 Publicly-Listed Biotechs Companies 30.8x
Australia Market PE Ratio Median Figure of 519 Publicly-Listed Companies 18.63x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Cellmid.

ASX:CDY PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= ASX:CDY Share Price ÷ EPS (both in AUD)

= 0.23 ÷ -0.08

-2.95x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Cellmid is loss making, we can't compare its value to the Global Biotechs industry average.
  • Cellmid is loss making, we can't compare the value of its earnings to the Australia market.
Price based on expected Growth
Does Cellmid's expected growth come at a high price?
Raw Data
ASX:CDY PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -2.95x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
Global Biotechs Industry PEG Ratio Median Figure of 85 Publicly-Listed Biotechs Companies 1.39x
Australia Market PEG Ratio Median Figure of 347 Publicly-Listed Companies 1.58x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Cellmid, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Cellmid's assets?
Raw Data
ASX:CDY PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-06-30) in AUD A$0.07
ASX:CDY Share Price * ASX (2019-11-17) in AUD A$0.23
Australia Biotechs Industry PB Ratio Median Figure of 38 Publicly-Listed Biotechs Companies 3.17x
Australia Market PB Ratio Median Figure of 1,584 Publicly-Listed Companies 1.75x
ASX:CDY PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= ASX:CDY Share Price ÷ Book Value per Share (both in AUD)

= 0.23 ÷ 0.07

3.3x

* Primary Listing of Cellmid.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Cellmid is overvalued based on assets compared to the AU Biotechs industry average.
X
Value checks
We assess Cellmid's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Cellmid has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Cellmid expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Cellmid has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
13%
Expected Biotechs industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Cellmid expected to grow at an attractive rate?
  • Unable to compare Cellmid's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Cellmid's earnings growth to the Australia market average as no estimate data is available.
  • Unable to compare Cellmid's revenue growth to the Australia market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
ASX:CDY Future Growth Rates Data Sources
Data Point Source Value (per year)
Australia Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 13%
Australia Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 10.3%
Australia Market Earnings Growth Rate Market Cap Weighted Average 9.7%
Australia Market Revenue Growth Rate Market Cap Weighted Average 3.7%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
ASX:CDY Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in AUD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
ASX:CDY Past Financials Data
Date (Data in AUD Millions) Revenue Cash Flow Net Income *
2019-06-30 7 -6 -6
2019-03-31 7 -6 -6
2018-12-31 6 -6 -6
2018-09-30 6 -5 -5
2018-06-30 6 -4 -4
2018-03-31 6 -4
2017-12-31 6 -4 -4
2017-09-30 5 -4 -4
2017-06-30 5 -4 -4
2017-03-31 4 -4 -4
2016-12-31 4 -3 -3
2016-09-30 4 -3 -3

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Cellmid is high growth as no earnings estimate data is available.
  • Unable to determine if Cellmid is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
ASX:CDY Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Cellmid Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

ASX:CDY Past Financials Data
Date (Data in AUD Millions) EPS *
2019-06-30 -0.08
2019-03-31 -0.08
2018-12-31 -0.09
2018-09-30 -0.08
2018-06-30 -0.07
2018-03-31 -0.07
2017-12-31 -0.08
2017-09-30 -0.08
2017-06-30 -0.09
2017-03-31 -0.08
2016-12-31 -0.07
2016-09-30 -0.07

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Cellmid will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Take a look at our analysis of CDY’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  2. Cellmid's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Pharmaceuticals & Biotech companies here
  3. Cellmid's competitive advantages and company strategy can generally be found in its financial reports archived here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess Cellmid's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Australia market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Australia market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Cellmid has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Cellmid performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Cellmid's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Cellmid does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Cellmid's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Cellmid's 1-year growth to the Global Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Cellmid's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Cellmid Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

ASX:CDY Past Revenue, Cash Flow and Net Income Data
Date (Data in AUD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-06-30 7.46 -5.91 7.09 0.85
2019-03-31 6.79 -6.03 7.94 0.79
2018-12-31 6.10 -6.15 8.93 0.72
2018-09-30 5.91 -4.94 7.71 0.66
2018-06-30 5.74 -3.73 6.35 0.62
2018-03-31 5.72 -3.90 6.39 0.67
2017-12-31 5.69 -4.06 6.43 0.72
2017-09-30 5.18 -4.27 6.29 0.66
2017-06-30 4.67 -4.48 6.14 0.60
2017-03-31 4.40 -3.88 5.90 0.46
2016-12-31 4.14 -3.28 5.67 0.31
2016-09-30 3.74 -3.39 5.74 0.33
2016-06-30 3.35 -3.50 5.81 0.35
2016-03-31 3.00 -3.78 5.49 0.70
2015-12-31 2.65 -4.07 5.17 1.05
2015-09-30 2.30 -3.70 4.42 1.18
2015-06-30 1.94 -3.34 3.67 1.30
2015-03-31 1.65 -3.03 3.53 1.13
2014-12-31 1.35 -2.72 3.39 0.96
2014-09-30 1.77 -2.09 3.36 0.88
2014-06-30 2.20 -1.47 3.33 0.81
2014-03-31 2.00 -1.19 3.19 0.67
2013-12-31 1.81 -0.90 3.06 0.53
2013-09-30 1.18 -1.21 2.65 0.50
2013-06-30 0.54 -1.53 2.25 0.48
2013-03-31 0.44 -1.61 2.13 0.56
2012-12-31 0.33 -1.70 2.01 0.65

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Cellmid has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Cellmid has efficiently used its assets last year compared to the Global Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Cellmid improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Cellmid's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Cellmid has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Cellmid's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Cellmid's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Cellmid is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Cellmid's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Cellmid's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is covered by short term assets, assets are 5.6x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Cellmid Company Filings, last reported 4 months ago.

ASX:CDY Past Debt and Equity Data
Date (Data in AUD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-06-30 5.86 1.29 3.08
2019-03-31 5.86 1.29 3.08
2018-12-31 8.18 1.13 5.41
2018-09-30 8.18 1.13 5.41
2018-06-30 1.86 3.17 1.61
2018-03-31 1.86 3.17 1.61
2017-12-31 4.59 2.42 3.51
2017-09-30 4.59 2.42 3.51
2017-06-30 4.07 2.16 3.99
2017-03-31 4.40 2.16 3.99
2016-12-31 7.07 1.20 5.35
2016-09-30 7.07 1.20 5.35
2016-06-30 4.69 1.00 2.69
2016-03-31 4.69 1.00 2.69
2015-12-31 5.97 1.30 4.52
2015-09-30 5.97 1.30 4.52
2015-06-30 3.77 1.10 1.58
2015-03-31 3.77 1.10 1.58
2014-12-31 5.92 0.00 2.69
2014-09-30 5.92 0.00 2.69
2014-06-30 5.66 0.00 2.50
2014-03-31 5.66 0.00 2.50
2013-12-31 7.58 0.00 4.07
2013-09-30 7.58 0.00 4.07
2013-06-30 5.31 0.00 1.75
2013-03-31 5.31 0.00 1.75
2012-12-31 2.62 0.00 1.78
  • Cellmid's level of debt (22%) compared to net worth is satisfactory (less than 40%).
  • Unable to establish if Cellmid's debt level has increased without past 5-year debt data.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Cellmid has less than a year of cash runway based on current free cash flow.
  • Cellmid has less than a year of cash runway if free cash flow continues to grow at historical rates of 26.2% each year.
X
Financial health checks
We assess Cellmid's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Cellmid has a total score of 3/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Cellmid's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Cellmid dividends.
If you bought A$2,000 of Cellmid shares you are expected to receive A$0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Cellmid's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Cellmid's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
ASX:CDY Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
Global Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 59 Stocks 2.1%
Australia Market Average Dividend Yield Market Cap Weighted Average of 390 Stocks 4%
Australia Minimum Threshold Dividend Yield 10th Percentile 1.5%
Australia Bottom 25% Dividend Yield 25th Percentile 2.4%
Australia Top 25% Dividend Yield 75th Percentile 5.6%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Cellmid has not reported any payouts.
  • Unable to verify if Cellmid's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Cellmid's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Cellmid has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Cellmid's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.5%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Cellmid afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Cellmid has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Cellmid's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Maria Halasz
COMPENSATION A$681,452
TENURE AS CEO 12.6 years
CEO Bio

Ms. Maria Halasz, MBA, BSc, has been the Chief Executive Officer of Cellmid Limited since April 14, 2007 and has been its Managing Director since November 2007. Ms. Halasz served as Managing Director of Medical Therapies Inc., since April 16, 2007. Ms. Halasz has been a venture partner at the Emerging Technology Fund of venture capital firm Allen and Buckeridge. She has been involved with biotechnology companies for 18 years initially working in executive positions in biotechnology firms, managing funds in the life sciences sector and senior positions in corporate finance. Prior to joining Medical Therapies, Ms. Halasz served as an adviser to an independent sector based research firm in life sciences and managed Direct Capital Group Pty Ltd., a specialist biotechnology fund. She has been an Executive Director at Cellmid Limited since November 19, 2007. She has science and business qualifications and many years of industry experience. She is a Member of the Australian Institute of Company Directors and holds a science Degree in microbiology from University of Western Australia and holds an MBA.

CEO Compensation
  • Maria's compensation has increased whilst company is loss making.
  • Maria's remuneration is higher than average for companies of similar size in Australia.
Management Team Tenure

Average tenure of the Cellmid management team in years:

1.2
Average Tenure
  • The average tenure for the Cellmid management team is less than 2 years, this suggests a new team.
Management Team

Maria Halasz

TITLE
CEO, MD & Executive Director
COMPENSATION
A$681K
TENURE
12.6 yrs

Bart Wuurman

TITLE
Chief Executive Officer of Lyramid
COMPENSATION
A$288K
TENURE
0.4 yrs

Ko Koike

TITLE
Managing Director of Advangen Inc
COMPENSATION
A$283K
AGE
62

Graham Robertson

TITLE
Head of Research & Development

Lee Tamplin

TITLE
Company Secretary
TENURE
1.2 yrs

Brian McGee

TITLE
CEO of Advangen LLC
Board of Directors Tenure

Average tenure of the Cellmid board of directors in years:

4.3
Average Tenure
  • The tenure for the Cellmid board of directors is about average.
Board of Directors

Dave King

TITLE
Non-Executive Chairman
COMPENSATION
A$71K
AGE
72
TENURE
11.8 yrs

Maria Halasz

TITLE
CEO, MD & Executive Director
COMPENSATION
A$681K
TENURE
12 yrs

Bruce Gordon

TITLE
Non-Executive Director
COMPENSATION
A$50K
TENURE
4.3 yrs

Bryce Vissel

TITLE
Chairman of Scientific Advisory Board
TENURE
4.6 yrs

Fintan Walton

TITLE
Non-Executive Director
COMPENSATION
A$50K
TENURE
4.3 yrs

Martin Cross

TITLE
Non-Executive Director
COMPENSATION
A$55K
TENURE
2.1 yrs

Dennis Eck

TITLE
Non-Executive Director
COMPENSATION
A$49K
AGE
76
TENURE
1.7 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (A$) Value (A$)
07. Jun 19 Buy Maria Halasz Individual 31. May 19 31. May 19 12,000 A$0.19 A$2,280
06. May 19 Buy Maria Halasz Individual 29. Apr 19 29. Apr 19 39,000 A$0.21 A$8,190
18. Apr 19 Sell Maria Halasz Individual 15. Apr 19 15. Apr 19 -400,000 A$0.21 A$-86,000
X
Management checks
We assess Cellmid's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Cellmid has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

The Cellmid (ASX:CDY) Share Price Is Down 64% So Some Shareholders Are Wishing They Sold

While it may not be enough for some shareholders, we think it is good to see the Cellmid Limited (ASX:CDY) share price up 18% in a single quarter. … Unfortunately for shareholders the share price has dropped 19% per year - disappointing considering the growth. … Cellmid is not the only stock insiders are buying.

Simply Wall St -

Who Has Been Buying Cellmid Limited (ASX:CDY) Shares?

So we'll take a look at whether insiders have been buying or selling shares in Cellmid Limited (ASX:CDY). … For example, a Harvard University study found that 'insider purchases earn abnormal returns of more than 6% per year.' Check out our latest analysis for Cellmid The Last 12 Months Of Insider Transactions At Cellmid In the last twelve months, the biggest single purchase by an insider was when Non-Executive Director Dennis Eck bought AU$1.0m worth of shares at a price of AU$0.38 per share. … In the last twelve months there was more buying than selling by Cellmid insiders.

Simply Wall St -

Is Cellmid (ASX:CDY) A Risky Investment?

Debt and other liabilities become risky for a business when it cannot easily fulfill those obligations, either with free cash flow or by raising capital at an attractive price. … ASX:CDY Historical Debt, July 12th 2019 A Look At Cellmid's Liabilities The latest balance sheet data shows that Cellmid had liabilities of AU$2.29m due within a year, and liabilities of AU$941.8k falling due after that. … It's good to see that Cellmid has plenty of liquidity on its balance sheet, suggesting conservative management of liabilities.

Simply Wall St -

What Did Cellmid Limited's (ASX:CDY) CEO Take Home Last Year?

See our latest analysis for Cellmid How Does Maria Halasz's Compensation Compare With Similar Sized Companies? … Thus we can conclude that Maria Halasz receives more in total compensation than the median of a group of companies in the same market, and of similar size to Cellmid Limited. … We compared total CEO remuneration at Cellmid Limited with the amount paid at companies with a similar market capitalization.

Simply Wall St -

Cellmid Limited (ASX:CDY) Insiders Increased Their Holdings

That means that even when the share price was higher than AU$0.23 (the recent price), an insider wanted to purchase shares. … In our view, the price an insider pays for shares is very important. … As a general rule, we feel more positive about a stock if insiders have bought shares at above current prices, because that suggests they viewed the stock as good value, even at a higher price

Simply Wall St -

Should You Be Pleased About The CEO Pay At Cellmid Limited's (ASX:CDY)

How Does Maria Halasz's Compensation Compare With Similar Sized Companies. … At the time of writing our data says that Cellmid Limited has a market cap of AU$19m, and is paying total annual CEO compensation of AU$474k. … We examined a group of similar sized companies, with market capitalizations of below AU$282m

Simply Wall St -

What Kind Of Shareholder Owns Most Cellmid Limited (ASX:CDY) Stock?

Institutions often own shares in more established companies, while it's not unusual to see insiders own a fair bit of smaller companies. … Cellmid is a smaller company with a market capitalization of AU$18m, so it may still be flying under the radar of many institutional investors. … institutions don't own many shares in the company

Simply Wall St -

Cellmid Limited (ASX:CDY) Insiders Increased Their Holdings

We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. … Most investors know that it is quite permissible for company leaders, such as directors of the board, to buy and sell stock on the market. … As Peter Lynch said, 'insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.'?

Simply Wall St -

Is Cellmid Limited's (ASX:CDY) CEO Paid Enough Relative To Peers?

First, this article will compare CEO compensation with compensation at similar sized companies. … How Does Maria Halasz's Compensation Compare With Similar Sized Companies. … According to our data, Cellmid Limited has a market capitalization of AU$23m, and pays its CEO total annual compensation worth AU$474k.

Simply Wall St -

Who Are The Major Shareholders In Cellmid Limited (ASX:CDY)?

In this article, I will take a quick look at Cellmid Limited’s (ASX:CDY) recent ownership structure – an unconventional investing subject, but an important one. … When it comes to ownership structure of a company, the impact has been observed in both the long-and short-term performance of shares. … It also impacts the trading environment of company shares, which is more of a concern for short-term investors.

Simply Wall St -

Company Info

Description

Cellmid Limited, a life sciences company, develops and commercializes diagnostic and therapeutic products for cancer and various chronic inflammatory conditions in Australia, the United States, and Japan. The company offers Midkine (MK) ELISA Kit, a cancer biomarker, and diagnostic and prognostic tool. It is also developing CAB102, a humanized monoclonal antibody for use in solid tumors; CAB101, a monoclonal antibody for the treatment of kidney injury, and inflammatory and fibrotic diseases; and CMK103, a recombinant human form of MK protein for use in cardiac ischemia. In addition, the company develops and sells over-the-counter products; and a range of FGF5 inhibitor hair growth products. Cellmid Limited was incorporated in 2004 and is based in Sydney, Australia.

Details
Name: Cellmid Limited
CDY
Exchange: ASX
Founded: 2004
A$21,454,279
93,279,475
Website: http://www.cellmid.com.au
Address: Cellmid Limited
55 Clarence Street,
Suite 204,
Sydney,
New South Wales, 2000,
Australia
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
ASX CDY Ordinary Shares Australian Securities Exchange AU AUD 09. Dec 2005
CHIA CDY Ordinary Shares Chi-X Australia AU AUD 09. Dec 2005
Number of employees
Current staff
Staff numbers
0
Cellmid employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/11/18 10:33
End of day share price update: 2019/11/17 00:00
Last earnings filing: 2019/08/28
Last earnings reported: 2019/06/30
Last annual earnings reported: 2019/06/30


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.